HEALTHCARE SYSTEM AND SOCIETAL RESOURCE REQUIREMENTS ASSOCIATED WITH INTRAVENOUS IMMUNOGLOBULIN TREATMENT FOR PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Author(s)
Marie-Hélène Lafeuille, MSc1, Guyllaume Faucher, MSc1, Eric Chaloux, BSc2, Julien Patris, MSc Econ3.
1AppEco, Montreal, QC, Canada, 2argenx, Vaughan, ON, Canada, 3argenx, Ghent, Belgium.
1AppEco, Montreal, QC, Canada, 2argenx, Vaughan, ON, Canada, 3argenx, Ghent, Belgium.
OBJECTIVES: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder affecting the peripheral nervous system. A common maintenance therapy is intravenous immunoglobulin (IVIg), a plasma-derived medicinal product whose production relies on human plasma donors. This study aimed to estimate the healthcare system and societal resources associated with IVIg treatment in patients with CIDP in selected markets.
METHODS: A resource utilization model was developed from a societal perspective to quantify healthcare system and societal resources required to treat patients with CIDP receiving IVIg in Canada, Italy, the Netherlands, and the United Kingdom. Data sources included blood agencies, reports and published literature. Healthcare resource use reported included treatment visits and infusion chair time. Societal resource use included patient and caregiver (for 25% of patients) time associated with IVIg administration, and plasma donor efforts required to produce IVIg.
RESULTS: Each patient with CIDP received 13-29 IVIg treatment visits per year, corresponding to 61-149 hours of infusion chair capacity annually. Including travel and caregiver support, each patient and their caregiver spent an estimated 90-211 hours per year on treatment-related activities. Assuming each donation yields 3.825 g of Ig, producing the IVIg required for a single patient necessitated 363-759 plasma donations annually, corresponding to 604-1,265 hours of donor time, or approximately 0.3-0.6 full-time equivalent (FTE) years. Donor time was about seven times greater than the time spent by patients and caregivers.
CONCLUSIONS: The societal burden associated with IVIg treatment for CIDP extends beyond patient care and encompasses considerable resource requirements across the plasma supply chain. These findings underscore the importance of evaluating treatment strategies not only in terms of clinical outcomes, but also their impact on healthcare resource utilization and dependence on plasma-derived products.
METHODS: A resource utilization model was developed from a societal perspective to quantify healthcare system and societal resources required to treat patients with CIDP receiving IVIg in Canada, Italy, the Netherlands, and the United Kingdom. Data sources included blood agencies, reports and published literature. Healthcare resource use reported included treatment visits and infusion chair time. Societal resource use included patient and caregiver (for 25% of patients) time associated with IVIg administration, and plasma donor efforts required to produce IVIg.
RESULTS: Each patient with CIDP received 13-29 IVIg treatment visits per year, corresponding to 61-149 hours of infusion chair capacity annually. Including travel and caregiver support, each patient and their caregiver spent an estimated 90-211 hours per year on treatment-related activities. Assuming each donation yields 3.825 g of Ig, producing the IVIg required for a single patient necessitated 363-759 plasma donations annually, corresponding to 604-1,265 hours of donor time, or approximately 0.3-0.6 full-time equivalent (FTE) years. Donor time was about seven times greater than the time spent by patients and caregivers.
CONCLUSIONS: The societal burden associated with IVIg treatment for CIDP extends beyond patient care and encompasses considerable resource requirements across the plasma supply chain. These findings underscore the importance of evaluating treatment strategies not only in terms of clinical outcomes, but also their impact on healthcare resource utilization and dependence on plasma-derived products.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE204
Topic
Economic Evaluation, Health Policy & Regulatory
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Neurological Disorders